The fair value estimate for MoonLake Immunotherapeutics matches the analyst price target at US$73.92. By utilizing the Discounted Cash Flow model, the intrinsic value of the stock is calculated based on future cash flows, considering growth rates and discounting to present value.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing